Opinion

Video

The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

Panelists discuss their overall perceptions of oral selective estrogen receptor degraders (SERDs) and their impact on the treatment landscape and share their experiences with elacestrant in clinical practice.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    Dr. Bardia to All Panelists:

    • What is your overall perception on the class of oral SERDs?
    • How will they continue to impact the treatment landscape?
    • What has your experience been in practice with elacestrant?